Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: A system for intervention in visceral leishmaniasis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 11, 2012, Pages 2650-2660

  Kansal, Shaswat ^a   Tandon, Rati ^a   Dwivedi, Pankaj ^a   Misra, Pragya ^a   Verma, P R P ^b   Dube, Anuradha ^a   Mishra, Prabhat Ranjan ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Amastigotes; J774A.1 cell lines; L. donovani; Layer by layer assembly; Polyelectrolytes

Indexed keywords

ANTILEISHMANIAL AGENT; DOXORUBICIN; NANOCAPSULE; PHOSPHATIDYLSERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL LINE; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG UPTAKE; FLOW CYTOMETRY; HAMSTER; LEISHMANIA DONOVANI; MACROPHAGE; MALE; NONHUMAN; PARASITE LOAD; RAT; SPLEEN; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; CRICETINAE; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG CARRIERS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGES; MALE; MESOCRICETUS; NANOCAPSULES; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 84867612021     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks286     Document Type: Article

References (57)

1. Trotter ER, Peters W, Robinson BL. The experimental chemotherapy of leishmaniasis, IV. The development of a rodent model for visceral infection. Ann Trop Med Parasitol 1980; 74: 127-38.
2. Badaró R, Jones TC, Lorenço R et al. A prospective study of visceral leishmaniasis in an endemic area of Brazil. J Infect Dis 1986; 154: 639-49.
3. Chono S, Tanino T, Seki T et al. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J Control Release 2008; 127: 50-8.
4. Kole L, Das L, Das PK. Synergistic effect of interferon-g and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis. J Infect Dis 1999; 180: 811-20.
5. Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv 2011; 2011: 727241.
6. Ravichandran KS, Lorenz U. Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol 2007; 7: 964-74.
7. Fadok V, Voelker D, Campbell P et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148: 2207-16.
8. Wu Y, Tibrewal N, Birge RB. Phosphatidylserine recognition by phagocytes: a view to a kill. Trends Cell Biol 2006; 16: 189-97.
9. Fadok V, Bratton D, Frasch S et al. The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell Death Differ 1998; 5: 551-62.
10. Mietto L, Boarato E, Toffano G et al. Internalization of phosphatidylserine by adherent and non-adherent rat mononuclear cells. Biochim Biophys Acta 1989; 1013: 1-6.
11. Fidler IJ, Raz A, Fogler WE et al. Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Res 1980; 40: 4460-6.
12. Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 2002; 15: 593-8.
13. Gille L, Nohl H. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic Biol Med 1997; 23: 775-82.
14. Sett R, Basu N, Ghosh AK et al. Potential of doxorubicin as an antileishmanial agent. J Parasitol 1992; 78: 350-4.
15. Sanchez-Brunete JA, Dea MA, Rama S et al. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother 2004; 48: 3246-52.
16. Tardi P, Boman N, Cullis P. Liposomal doxorubicin. J Drug Target 1996; 4: 129-40.
17. Gupta GK, Kansal S, Misra P et al. Uptake of biodegradable gel-assisted LBL nanomatrix by Leishmania donovani-infected macrophages. AAPS PharmSciTech 2009; 10: 1343-7.
18. Tewes F, Munnier E, Antoon B et al. Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by singleanddouble emulsionmethods. Eur J PharmBiopharm2007;66:488-92.
19. Liu W, Sun D, Li C et al. Formation and stability of paraffin oil-in-water nano-emulsions prepared by the emulsion inversion point method. J Colloid Interface Sci 2006; 303: 557-63.
20. Kataoka K, Matsumoto T, Yokoyama M et al. Doxorubicin-loaded poly(ethylene glycol)-poly(β-benzyl-l-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Control Release 2000; 64: 143-53.
21. Moya S, Donath E, Sukhorukov GB et al. Lipid coating on polyelectrolyte surface modified colloidal particles and polyelectrolyte capsules. Macromolecules 2000; 33: 4538-44.
22. Hartmann G, Vassileva V, Piquette-Miller M. Impact of endotoxin-induced changes in P-glycoprotein expression on disposition of doxorubicin in mice. Drug Metab Dispos 2005; 33: 820-8.
23. Duverger A, Jackson RJ, van Ginkel FW et al. Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol 2006; 176: 1776-83.
24. Albright CF, Graciani N, Han W, et al. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. Mol Cancer Ther 2005; 4: 751-60.
25. Pal R, Anuradha, Rizvi SY et al. Leishmania donovani in hamsters: stimulation of non-specific resistance by some novel glycopeptides and impact on therapeutic efficacy. Experientia 1991; 47: 486-90.
26. Seymour AA, Sheldon JH, Smith PL et al. Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anesthetized dogs. J Pharmacol Exp Ther 1994; 269: 263-70.
27. Fundaro' A, Cavalli R, Bargoni A et al. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 2000; 42: 337-43.
28. Á lvarez-Cedrón L, Sayalero ML, Lanao JM. High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues. J Chromatogr B Biomed Sci Appl 1999; 721: 271-8.
29. Dube A, Sharma P, Srivastava JK et al. Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology 1998; 116: 219-21.
30. Dube A, Srivastava JK, Sharma P et al. Leishmania donovani: cellular and humoral immune responses in Indian langur monkeys, Presbytis entellus. Acta Trop 1999; 73: 37-48.
31. Dube A, Singh N, Sundar S et al. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res 2005; 96: 216-23.
32. Guru PY, Agrawal AK, Singha UK et al. Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles. FEBS Lett 1989; 245: 204-8.
33. Wang J-J, Sung KC, Hu OY-P et al. Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs. J Control Release 2006; 115: 140-9.
34. Tiuman TS, Santos AO, Ueda-Nakamura T et al. Recent advances in leishmaniasis treatment. Int J Infect Dis 2011; 15: e525-e32.
35. Romero EL, Morilla MJ. Drug delivery systems against leishmaniasis? Still an open question. Expert Opin Drug Deliv 2008; 5: 805-23.
36. Shukla A, Patra S, Dubey V. Evaluation of selected antitumor agents as subversive substrate and potential inhibitor of trypanothione reductase: an alternative approach for chemotherapy of leishmaniasis. Mol Cell Biochem 2011; 352: 261-70.
37. Shukla P, Gupta G, Singodia D et al. Emerging trend in nano-engineered polyelectrolyte-based surrogate carriers for delivery of bioactives. Expert Opin Drug Deliv 2010; 7: 993-1011.
38. Decher G. Fuzzy nanoassemblies: toward layered polymeric multicomposites. Science 1997; 277: 1232-7.
39. Decher G, Eckle M, Schmitt J et al. Layer-by-layer assembled multicomposite films. Curr Opin Colloid Interface Sci 1998; 3: 32-9.
40. Dubas ST, Schlenoff JB. Factors controlling the growth of polyelectrolyte multilayers. Macromolecules 1999; 32: 8153-60.
41. Date AA, Joshi MD, Patravale VB. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 2007; 59: 505-21.
42. Sukhorukov GB, Donath E, Davis S et al. Stepwise polyelectrolyte assembly on particle surfaces: a novel approach to colloid design. Polym Adv Technol 1998; 9: 759-67.
43. Volodkin DV, Petrov AI, Prevot M et al. Matrix polyelectrolyte microcapsules: new system for macromolecule encapsulation. Langmuir 2004; 20: 3398-406.
44. Vdović N, Kralj D. Electrokinetic properties of spontaneously precipitated calcium carbonate polymorphs: the influence of organic substances. Colloids Surf E Physicochem Eng Asp 2000; 161: 499-505.
45. Romero G, Estrela-Lopis I, Castro-Hartmann P et al. Stepwise surface tailoring of carbon nanotubes with polyelectrolyte brushes and lipid layers to control their intracellular distribution and 'in vitro' toxicity. Soft Matter 2011; 7: 6883-90.
46. Vermes I, Haanen C, Steffens-Nakken H et al. A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 1995; 184: 39-51.
47. Khan MA, Owais M. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model. J Antimicrob Chemother 2006; 58: 125-32.
48. Nagata K, Ohashi K, Nakano T et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 1996; 271: 30022-7.
49. Anderson HA, Maylock CA, Williams JA et al. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat Immunol 2003; 4: 87-91.
50. Hanayama R, Tanaka M, Miwa K et al. Identification of a factor that links apoptotic cells to phagocytes. Nature 2002; 417: 182-7.
51. Park D, Tosello-Trampont A-C, Elliott MR et al. BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature 2007; 450: 430-4.
52. Rigotti A, Acton SL, Krieger M. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem 1995; 270: 16221-4.
53. Tempone AG, Perez D, Rath S et al. Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine. J Antimicrob Chemother 2004; 54: 60-8.
54. Nacy CA, Meltzer MS, Fortier AH. Macrophage activation to kill Leishmania tropica: characterization of P/J mouse macrophage defects for lymphokine-induced antimicrobial activities against Leishmania tropica amastigotes. J Immunol 1984; 133: 3344-50.
55. Mukbel RM, Patten C, Gibson K et al. Macrophage killing of Leishmania amazonensis amastigotes requires both nitric oxide and superoxide. Am J Trop Med Hyg 2007; 76: 669-75.
56. Takakura K, Mizogami M, Fukuda S. Protamine sulfate causes endothelium-independent vasorelaxation via inducible nitric oxide synthase pathway. Can J Anaesth 2006; 53: 162-7.
57. Son EH, Moon EY, Rhee DK et al. Stimulation of various functions in murine peritoneal macrophages by high mannuronic acid-containing alginate (HMA) exposure